Abstract: A biocompatible magnetic material containing an iron oxide nanoparticle and one or more biocompatible polymers, each having formula (I) below, covalently bonded to the iron oxide nanoparticle: in which each of variables R, L, x, and y is defined herein, the biocompatible magnetic material contains 4-15% Fe(II) ions relative to the total iron ions. Also disclosed in a method of preparing the biocompatible magnetic material.

Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

Abstract: A biocompatible magnetic material containing an iron oxide nanoparticle and one or more biocompatible polymers, each having formula (I) below, covalently bonded to the iron oxide nanoparticle: in which each of variables R, L, x, and y is defined herein, the biocompatible magnetic material contains 4-15% Fe(II) ions relative to the total iron ions. Also disclosed in a method of preparing the biocompatible magnetic material.

Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

Abstract: A biocompatible magnetic material containing an iron oxide nanoparticle and one or more biocompatible polymers, each having formula (I) below, covalently bonded to the iron oxide nanoparticle: in which each of variables R, L, x, and y is defined herein, the biocompatible magnetic material contains 4-15% Fe(II) ions relative to the total iron ions. Also disclosed in a method of preparing the biocompatible magnetic material.

Abstract: A directly compressed extended release cyclobenzaprine tablet and method for making the tablet that includes homogenously mixing: (i) cyclobenzaprine, (ii) a filler selected from the group consisting of lactose, spray-dried lactose, mannitol, and combinations thereof; and (iii) a glidant selected from the group consisting of silica, peptized silica, and combinations thereof; and (iv) hydroxypropyl methylcellulose (HPMC) to provide a first mixture; homogenously mixing a lubricant with the first mixture to provide a second mixture; and directly compressing the second mixture into a tablet, having a ratio of filler to matrix forming polymer ranges from 1.66 to 2.07.

Abstract: The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Abstract: The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Abstract: A process for synthesizing and screening solution phase derived libraries of fenbufen and ethacrynic acid is provided in the present invention. Compounds in the present invention having cytotoxicities are useful for a variety of therapeutic applications.

Abstract: A process for synthesizing and screening solution phase derived libraries of fenbufen and ethacrynic acid is provided in the present invention. Compounds in the present invention having cytotoxicities are useful for a variety of therapeutic applications.

Abstract: An amide-based library is disclosed in the invention which is prepared via amide bond formation coupling an amine with a carboxylic acid. Also, a method using said library for screening a drug candidate is provided in the present invention. Compounds in the present invention having cytotoxicities are useful for a variety of therapeutic applications.

Abstract: A printed circuit board assembly includes a central board and a peripheral board. The central board comprises a first connector, and is mounted with one or more of a CPU, memory, a north bridge chipset, and a south bridge chipset. The peripheral board is separated from the central board. The peripheral board comprises a second connector, and is mounted with a power source connector, a video chipset, an audio chipset, and a network card. The second connector is connected to the first connector to achieve communication between the central board and the peripheral board. The first connector and the second connector transmits one or more of DVP signals, VGA signals, SATA signals, LCD controlling signals, audio signals, speaker output signals, PCIE signals, LPC signals, PCI signals, video general input/output signals, USB signals between the central board and the peripheral board.

Abstract: A circuit for protecting a computer whose CPU power-on voltage on a motherboard is abnormal, includes a first transistor (Q1), a second transistor (Q2), and a third transistor (Q3). A base of the first transistor receives a signal to indicate the status of the CPU power-on voltage, and an emitter is connected to a ground. A base of the second transistor is connected to a collector of the first transistor, an emitter is connected to the ground, and a collector is connected to a control terminal (25) for creating a control signal. An emitter of the third transistor is connected to the collector of the first transistor, a base receives a first assistant signal, and a collector receives a second assistant signal. When the CPU power-on voltage is abnormal, the first transistor is switched off, and the second and third transistors is switched on to create the control signal for shutting off the computer.